Detection and Characterization of Tumor Cells in Bone Marrow of Patients with Primary Breast Cancer

Diel, Ingo J.; Costa, Serban Dan; Kaufmann, M.; Bastert, G.

doi:10.1007/978-3-642-78596-2_4

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, in the cases with poorly differentiated cancer, bone metastasis primarily occurs through the vertebral vein system. ( 8 , 17 ) Several studies have reported that the vertebrae are the site where bone metastasis occurs most frequently, which supports that the vertebral vein system is the major route of bone metastasis. ( 9 , 12 , 18 ) Kusumoto et al( 10 ) have reported that in patients with gastric cancer, bone metastasis is more prevalent in the young age groups, but in our study, age was not found to be correlated with bone metastasis.…”

Section: Discussionmentioning

confidence: 88%

Bone Metastasis in Gastric Cancer Patients

Ahn

Kwon

2011

J Gastric Cancer

View full text Add to dashboard Cite

PurposeBone metastasis from stomach cancer occurs only rarely and it is known to have a very poor prognosis. This study examined the clinical characteristics and prognosis of patients who were diagnosed with stomach cancer and bone metastasis.Materials and MethodsThe subjects were 19 patients who were diagnosed with stomach cancer at Hanyang University Medical Center from June 1992 to August 2010 and they also had bone metastasis. The survival rate according to many clinicopathologic factors was retrospectively analyzed.Results11 patients out of 18 patients (61%) who received an operation were in stage IV and the most common bone metastasis location was the spine. Bone scintigraphy was mostly used for diagnosing bone metastasis and PET-CT and magnetic resonance imaging were used singly or together. The serum alkaline phosphatase at the time of diagnosis had increased in 12 cases and there were clinical symptoms (bone pain) in 16 cases. Treatment was given to 14 cases and it was mostly radiotherapy. There were 2 cases of discovering bone metastasis at the time of diagnosing stomach cancer. The interval after operation to the time of diagnosing bone metastasis for the 18 cases that received a stomach cancer operation was on average 14.9±17.3 months and the period until death after the diagnosis of bone metastasis was on average 3.8±2.6 months. As a result of univariate survival rate analysis, the group that was treated for bone metastasis had a significantly better survival period when the bone metastasis was singular rather than multiple, as compared to the non-treatment group, yet both factors were not independent prognosis factors on multivariate survival analysis.ConclusionsAn examination to confirm the status of bone metastasis when conducting a radio-tracer test after the initial diagnosis and also after an operation is needed for stomach cancer patients, and bone scintigraphy is the most helpfully modality. Making the diagnosis at the early stage and suitable treatments are expected to enhance the survival rate and improve the quality of life even for the patients with bone metastasis.

show abstract

Section: Discussionmentioning

confidence: 88%

Bone Metastasis in Gastric Cancer Patients

Ahn

Kwon

2011

J Gastric Cancer

View full text Add to dashboard Cite

show abstract

“…In our study, 76.3% of the patients received a radionuclide bone scan to screen for bone metastases, and 16.1% of the patients were diagnosed with bone metastases solely based on the radionuclide bone scan results, without confirmation by additional imaging techniques. Although the bone scan is a relatively sensitive and inexpensive examination that evaluates the entire skeleton, its false positive rate is very high, ranging from 30% to 40% [ 23 , 24 ]. Thus, the guidelines recommend that positive findings in the bone scan should be confirmed by X-ray radiography, magnetic resonance imaging (MRI), computed tomography (CT) scan, or positron emission tomography-computed tomography (PET-CT) [ 13 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Yang

Jin

et al. 2016

Chin J Cancer

View full text Add to dashboard Cite

BackgroundBone metastases are common in patients with advanced cancer. Bisphosphonates (BPs) could prevent or delay the development of skeleton-related events (SREs). The present study aimed to identify the clinical features of and treatment strategies for Chinese patients with bone metastases.MethodsConsecutive cancer patients who had bone metastases and received BP treatment were enrolled. A questionnaire was developed to collect the patients’ clinical data, as well as information on the diagnosis and management of bone metastases. Physicians’ awareness of the guidelines and knowledge of the application of BP were also assessed.ResultsA total of 3223 patients with lung cancer (36.5%), breast cancer (30.9%), prostate cancer (8.5%), and gastrointestinal cancer (5.7%) were included in this study. The sites of bone metastases were the thoracic spine (56.0 %), lumbar spine (47.1%), ribs (32.6%), and pelvis (23.2%). The SRE frequency was the highest in patients with multiple myeloma (36.6%), followed by those with lung cancer (25.9%), breast cancer (20.2%), prostate cancer (18.2%), and gastrointestinal cancer (17.3%). Irradiation to the bone was the most frequent SRE (58% in lung cancer patients, 45% in breast cancer patients, and 48% in prostate cancer patients). Our survey also showed that 45.5% of patients received BP within 3 months after their diagnosis of bone metastases, whereas the remaining 54.5% of patients did not receive BP treatment until at least 3 months after their diagnosis of bone metastases. The SRE frequency in the former group was significantly lower than that in the latter group (4.0% vs. 42.3%, P < 0.05). In patients with more than 6 months of continuous BP treatment, the mean time to the first SRE was significantly longer than that in patients with less than 6 months of continuous BP treatment (7.2 vs. 3.4 months, P < 0.05). In addition, 12.2% of the physicians were not aware of the efficacy of BP in preventing and delaying SRE. Only half (52.3%) of the physicians agreed that the BP treatment should persist for at least 6 months unless it was intolerable.ConclusionsOur study suggested that prompt and persistent BP treatment was associated with a reduced risk of SREs. However, our survey also revealed that the proper application of BP was not as common as expected in China.Electronic supplementary materialThe online version of this article (doi:10.1186/s40880-016-0102-6) contains supplementary material, which is available to authorized users.

show abstract

“…Even for early stages of carcinomas such as breast, gastric, colon, and lung cancers, investigations over the past decade have shown that single disseminated tumor cells can be detected easily with immunocytochemistry or polymerase chain reaction for epithelial cytokeratin markers. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] These methods were able to detect disseminated tumor cells within the mesenchymal background of the bone marrow at sufficient sensitivity and specificity.…”

mentioning

confidence: 99%

Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow

Heiss¹,

Simon²,

Beyer³

et al. 2002

JCO

View full text Add to dashboard Cite

This is the first large study to show that u-PAR, detected on disseminated tumor cells in the bone marrow, is an independent prognostic parameter in gastric cancer, in contrast to the mere detection of minimal residual disease (MRD). u-PAR may be a promising marker to define a critical subpopulation of disseminated tumor cells and a target to eliminate MRD. Molecular phenotyping of MRD is critical for defining its individual clinical relevance.

show abstract

Detection and Characterization of Tumor Cells in Bone Marrow of Patients with Primary Breast Cancer

Cited by 6 publications

References 24 publications

Bone Metastasis in Gastric Cancer Patients

Bone Metastasis in Gastric Cancer Patients

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow

Contact Info

Product

Resources

About